Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.LONA · Entity 1487 | CHIEF SCIENTIFIC OFFICER | April 09, 2026 | April 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date April 09, 2026 · Filed April 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.54 · Expires 2036-04-08 | Direct | 300,000 |
Reported balance
After 2026-04-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-09 · Grant · Acquired 300,000 · Balance 300,000 F1: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 09, 2026 Filed Apr 13, 2026 20:58 UTC | LeonaBio, Inc. LONA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $9.54 | $0.00 |
DisclosureSEC source: 0001822499-26-000006 · form4-04132026_080410.xml · derivative · entry 1 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-04-08 F1 · derivative.exercise_date: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 00:02 UTC | LeonaBio, Inc. LONA · Entity 1487 | SaleCommon Stock | 1,359 | $5.37 | $7,297.83 |
DisclosureSEC source: 0001822499-26-000004 · form4-03062026_120346.xml · nonDerivative · entry 2 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,178 F1 · kind: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:02 UTC | LeonaBio, Inc. LONA · Entity 1487 | Exercise / conversionRestricted Stock Units · Derivative | 5,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001822499-26-000004 · form4-03062026_120346.xml · derivative · entry 3 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,856 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F4 · derivative.exercise_date: On March 3, 2025, the reporting person was granted 5,856 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date. F4 · derivative.expiration_date: On March 3, 2025, the reporting person was granted 5,856 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:02 UTC | LeonaBio, Inc. LONA · Entity 1487 | Exercise / conversionCommon Stock | 5,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001822499-26-000004 · form4-03062026_120346.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 00:50 UTC | LeonaBio, Inc. ATHA · Entity 1487 | SaleCommon Stock | 876 | $6.88 | $6,026.88 |
DisclosureSEC source: 0001822499-26-000002 · form4-01062026_120110.xml · nonDerivative · entry 3 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,681 F5 · kind: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. entered into in connection with the Issuer's private placement in December 2025. F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 31, 2025 Filed Jan 6, 2026 00:50 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionRestricted Stock Units · Derivative | 3,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001822499-26-000002 · form4-01062026_120110.xml · derivative · entry 4 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: RSUs convert into common stock on a one-for-one basis. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F9 · derivative.exercise_date: On October 1, 2024, the reporting person was granted 11,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. F9 · derivative.expiration_date: On October 1, 2024, the reporting person was granted 11,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. Read SEC document |
| December 31, 2025 Filed Jan 6, 2026 00:50 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 3,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001822499-26-000002 · form4-01062026_120110.xml · nonDerivative · entry 2 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 21:15 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 35,138 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001822499-25-000005 · form4-12292025_091245.xml · derivative · entry 1 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,138 Underlying: Common Stock · 35,138 shares Expires 2035-09-23 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: On September 24, 2025, the reporting person was granted an option to purchase 35,138 shares of common stock. The option was scheduled to vest only upon satisfaction of both a milestone requirement (the "Milestone Requirement") and a service-based requirement (the "Service-Based Requirement"). The Milestone Requirement was satisfied on December 23, 2025. The Service-Based Requirement will be satisfied as to 50% of the total number of shares granted under the option on December 23, 2026 and as to 1/36th of the remaining 50% on the 23rd day of each month thereafter, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| November 18, 2025 Filed Jan 6, 2026 00:50 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 1,000 | $2.31 | $2,310.00 |
DisclosureSEC source: 0001822499-26-000002 · form4-01062026_120110.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,890 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 19, 2025 through November 18, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · security: The reported number of shares in this Form 4 has been adjusted to reflect the impact of the Issuer's 10-for-1 reverse stock split completed on September 17, 2025 (the "Reverse Stock Split"). F3 · date: The Purchase Period ended November 18, 2025 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 19, 2025. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:35 UTC | LeonaBio, Inc. ATHA · Entity 1487 | SaleCommon Stock | 8,526 | $0.29 | $2,502.38 |
DisclosureSEC source: 0001415889-25-019070 · form4-07022025_080725.xml · nonDerivative · entry 3 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,901 F4 · kind: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.2854 to $0.3031, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:35 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionRestricted Stock Units · Derivative | 36,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019070 · form4-07022025_080725.xml · derivative · entry 4 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,667 Underlying: Common Stock · 36,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: RSUs convert into common stock on a one-for-one basis. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F8 · derivative.exercise_date: On October 1, 2024, the reporting person was granted 110,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. F8 · derivative.expiration_date: On October 1, 2024, the reporting person was granted 110,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:35 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 36,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019070 · form4-07022025_080725.xml · nonDerivative · entry 2 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2025 Filed Jul 2, 2025 20:35 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 10,000 | $0.23 | $2,312.00 |
DisclosureSEC source: 0001415889-25-019070 · form4-07022025_080725.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,761 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"),for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2024 through May 19, 2025. This transaction is exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended March 19, 2025 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2024. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 19, 2025. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:30 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantRestricted Stock Units · Derivative | 58,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006552 · form4-03042025_090334.xml · derivative · entry 2 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,563 Underlying: Common Stock · 58,563 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F3 · derivative.exercise_date: 100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date. F3 · derivative.expiration_date: 100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:30 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 87,845 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001415889-25-006552 · form4-03042025_090334.xml · derivative · entry 1 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,845 Underlying: Common Stock · 87,845 shares Expires 2035-03-02 F1 · derivative.exercise_date: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:03 UTC | LeonaBio, Inc. ATHA · Entity 1487 | SaleCommon Stock | 8,510 | $0.56 | $4,781.77 |
DisclosureSEC source: 0001415889-25-000534 · form4-01032025_100111.xml · nonDerivative · entry 3 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,761 F4 · kind: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.5414 to $0.5939, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:03 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionRestricted Stock Units · Derivative | 36,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000534 · form4-01032025_100111.xml · derivative · entry 4 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,333 Underlying: Common Stock · 36,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: RSUs convert into common stock on a one-for-one basis. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F8 · derivative.exercise_date: On October 1, 2024, the reporting person was granted 110,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. F8 · derivative.expiration_date: On October 1, 2024, the reporting person was granted 110,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:03 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 36,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000534 · form4-01032025_100111.xml · nonDerivative · entry 2 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2024 Filed Jan 3, 2025 22:03 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 9,920 | $0.55 | $5,456.00 |
DisclosureSEC source: 0001415889-25-000534 · form4-01032025_100111.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,604 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 20, 2024 through November 18, 2024. This transaction is exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended November 18, 2024 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 20, 2024. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2024. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 23:10 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001415889-24-024684 · form4-10032024_111019.xml · derivative · entry 2 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2034-09-30 F3 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider through the applicable vesting dates. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 23:10 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantRestricted Stock Units · Derivative | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024684 · form4-10032024_111019.xml · derivative · entry 1 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F2 · derivative.exercise_date: One-third (1/3rd) of the RSUs shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. F2 · derivative.expiration_date: One-third (1/3rd) of the RSUs shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. Read SEC document |
| September 05, 2024 Filed Sep 5, 2024 23:49 UTC | LeonaBio, Inc. ATHA · Entity 1487 | SaleCommon Stock | 2,525 | $0.57 | $1,429.15 |
DisclosureSEC source: 0001415889-24-022985 · form4-09052024_110908.xml · nonDerivative · entry 3 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,684 F6 · kind: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of RSUs pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.5505 to $0.5751, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:49 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022985 · form4-09052024_110908.xml · nonDerivative · entry 2 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,209 F4 · date: On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs are scheduled to vest according to the following amended vesting schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest as of the date the Compensation Committee (the "Committee") determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (3) one third (1/3rd) of the number of shares subject to the RSU award vest as of the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout"), in each case subject to continued service with the Issuer through the applicable vesting date. F5 · shares: On September 3, 2024, the Company completed the public readout of the topline results of its LIFT-AD Phase 2/3 clinical trial and 10,000 RSUs vested on such date. Read SEC document |
| May 20, 2024 Filed Sep 5, 2024 23:49 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 4,953 | $1.34 | $6,637.02 |
DisclosureSEC source: 0001415889-24-022985 · form4-09052024_110908.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,209 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 20, 2023 through May 20, 2024. This transaction is exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended May 20, 2024 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 20, 2023. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 20, 2023. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:54 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 220,000 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001415889-24-004159 · form4-02162024_090202.xml · derivative · entry 1 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: Shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| January 05, 2024 Filed Feb 16, 2024 21:32 UTC Amendment | LeonaBio, Inc. ATHA · Entity 1487 | SaleCommon Stock | 2,412 | $2.91 | $7,018.92 |
DisclosureSEC source: 0001415889-24-004146 · form4a-02162024_090254.xml · nonDerivative · entry 4 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,256 F10 · date: The original Form 4 incorrectly reported the transaction date as 01/05/2023. F11 · kind: The reported shares were sold to cover the Issuer's tax withholding obligations in connection with the vesting of RSUs. Such sale was made pursuant to an Issuer-mandated policy and was not subject to discretion. F12 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $2.84 to $3.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 04, 2024 Filed Feb 16, 2024 21:32 UTC Amendment | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004146 · form4a-02162024_090254.xml · nonDerivative · entry 3 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,668 F7 · date: On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs are scheduled to vest according to the following amended vesting schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest as of the date the Compensation Committee (the "Committee") determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (3) one third (1/3rd) of the number of shares subject to the RSU award vest as of the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout"), in each case subject to continued service with the Issuer through the applicable vesting date. F8 · date: The original Form 4 incorrectly reported the transaction date as 01/04/2023. F9 · shares: On January 4, 2024, the Committee determined that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial had been completed and 10,000 RSUs vested and settled on such date. The original Form 4 incorrectly reported the determination date as January 4, 2023. Read SEC document |
| November 20, 2023 Filed Jan 8, 2024 21:36 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 3,397 | $1.34 | $4,551.98 |
DisclosureSEC source: 0001209191-24-001142 · doc4.xml · nonDerivative · entry 2 CHURCH KEVIN · CIK 0001822499 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,668 F4 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP, for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2023 through November 20, 2023. This transaction is also exempt under Rule 16b-3(c). F5 · date: The Purchase Period ended November 20, 2023 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2023. F6 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 20, 2023. Read SEC document |
| November 20, 2023 Filed Feb 16, 2024 21:32 UTC Amendment | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 3,397 | $1.34 | $4,551.98 |
DisclosureSEC source: 0001415889-24-004146 · form4a-02162024_090254.xml · nonDerivative · entry 2 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,668 F4 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP, for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2023 through November 20, 2023. This transaction is also exempt under Rule 16b-3(c). F5 · date: The Purchase Period ended November 20, 2023 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2023. F6 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 20, 2023. Read SEC document |
| May 18, 2023 Filed Jan 8, 2024 21:36 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 809 | $2.41 | $1,949.69 |
DisclosureSEC source: 0001209191-24-001142 · doc4.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,271 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2022 through May 18, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended May 18, 2023 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2022. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2023. Read SEC document |
| May 18, 2023 Filed Feb 16, 2024 21:32 UTC Amendment | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 809 | $2.41 | $1,949.69 |
DisclosureSEC source: 0001415889-24-004146 · form4a-02162024_090254.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,271 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2022 through May 18, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended May 18, 2023 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2022. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2023. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:57 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,410 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-23-021248 · doc4.xml · derivative · entry 2 CHURCH KEVIN · CIK 0001822499 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,410 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-fourth of the shares subject to the option vested on January 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:57 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 6,410 | $1.35 | $8,653.50 |
DisclosureSEC source: 0001209191-23-021248 · doc4.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 22:26 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001209191-23-004468 · doc4.xml · derivative · entry 2 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-01-18 F4 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter. Read SEC document |
| January 05, 2023 Filed Jan 8, 2024 21:36 UTC | LeonaBio, Inc. ATHA · Entity 1487 | SaleCommon Stock | 2,412 | $2.91 | $7,018.92 |
DisclosureSEC source: 0001209191-24-001142 · doc4.xml · nonDerivative · entry 4 CHURCH KEVIN · CIK 0001822499 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,256 F9 · kind: The reported shares were sold to cover the Issuer's tax withholding obligations in connection with the vesting of RSUs. Such sale was made pursuant to an Issuer-mandated policy and was not subject to discretion. F10 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $2.84 to $3.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 04, 2023 Filed Jan 8, 2024 21:36 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001142 · doc4.xml · nonDerivative · entry 3 CHURCH KEVIN · CIK 0001822499 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,668 F7 · date: On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs are scheduled to vest according to the following amended vesting schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest as of the date the Compensation Committee (the "Committee") determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (3) one third (1/3rd) of the number of shares subject to the RSU award vest as of the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout"), in each case subject to continued service with the Issuer through the applicable vesting date. F8 · shares: On January 4, 2023, the Committee determined that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial had been completed and 10,000 RSUs vested and settled on such date. Read SEC document |
| November 18, 2022 Filed Jan 23, 2023 22:26 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 657 | $2.74 | $1,800.18 |
DisclosureSEC source: 0001209191-23-004468 · doc4.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,052 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2022 through November 18, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended November 18, 2022 and is the sole Purchase Period in the Offering Period (as defined in the ESPP) that began May 18, 2022. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2022. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 00:17 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,700 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-22-054950 · doc4.xml · derivative · entry 2 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,410 Underlying: Common Stock · 3,700 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-fourth of the shares subject to the option vested on January 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 00:17 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 3,700 | $1.35 | $4,995.00 |
DisclosureSEC source: 0001209191-22-054950 · doc4.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 23:25 UTC | LeonaBio, Inc. ATHA · Entity 1487 | SaleCommon Stock | 2,614 | $2.69 | $7,031.66 |
DisclosureSEC source: 0001209191-22-039336 · doc4.xml · nonDerivative · entry 2 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,695 F2 · kind: The reported shares were sold to cover the Issuer's tax withholding obligations in connection with the vesting of RSUs. Such sale was made pursuant to an Issuer-mandated policy and was not subject to discretion. F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $2.62 to $2.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 23:25 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039336 · doc4.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,309 F1 · shares: On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs were scheduled to vest according to the following schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout") and (3) one third (1/3rd) of the number of shares subject to the RSU award vest six (6) months after the LIFT-AD Readout, in each case subject to continued service with the Issuer through the applicable vesting date. On June 22, 2022, the Issuer completed the public readout of topline results of the ACT-AD Phase 2 clinical trial and 10,000 RSUs vested and settled on such date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 21:53 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-22-036067 · doc4.xml · derivative · entry 3 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,110 Underlying: Common Stock · 2,500 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on January 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 21:53 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 2,500 | $1.35 | $3,375.00 |
DisclosureSEC source: 0001209191-22-036067 · doc4.xml · nonDerivative · entry 2 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2022 Filed Jun 10, 2022 21:53 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 243 | $7.06 | $1,715.58 |
DisclosureSEC source: 0001209191-22-036067 · doc4.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,809 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022. Read SEC document |
| February 18, 2022 Filed Feb 19, 2022 00:38 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,152 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-22-011485 · doc4.xml · derivative · entry 2 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,152 shares Expires 2027-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option fully vested on September 1, 2017. Read SEC document |
| February 18, 2022 Filed Feb 19, 2022 00:38 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 3,152 | $1.19 | $3,750.88 |
DisclosureSEC source: 0001209191-22-011485 · doc4.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:24 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001209191-22-004118 · doc4.xml · derivative · entry 2 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-01-17 F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter. Read SEC document |
| November 18, 2021 Filed Jan 20, 2022 22:24 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 96 | $12.51 | $1,200.96 |
DisclosureSEC source: 0001209191-22-004118 · doc4.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · Executive VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,414 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · deemedExecutionDate: The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:39 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,152 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-21-039242 · doc4.xml · derivative · entry 2 CHURCH KEVIN · CIK 0001822499 · Vice President of Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,152 shares Expires 2026-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option fully vested on September 1, 2016. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:39 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 3,152 | $1.04 | $3,278.08 |
DisclosureSEC source: 0001209191-21-039242 · doc4.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · Vice President of Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.